Esophageal pH Monitoring — CPB 0667 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0667 covering esophageal pH monitoring, effective February 24, 2026. Here's what billing teams need to do.

This update to Aetna's esophageal pH monitoring coverage policy refines medical necessity criteria across CPT codes 91034, 91035, 91037, 91038, and 91010. The policy draws clear lines between covered testing, non-covered indications, and procedures Aetna now considers experimental or investigational. If your practice bills these codes for gastroenterology, pulmonology, ENT, or pediatrics patients, audit your documentation protocols now — not after your first denial.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Esophageal pH Monitoring — CPB 0667
Policy Code	CPB 0667
Change Type	Modified
Effective Date	February 24, 2026
Impact Level	High
Specialties Affected	Gastroenterology, Pulmonology, ENT/Otolaryngology, Pediatrics, Thoracic Surgery
Key Action	Confirm PPI trial documentation and prior test results are in the chart before billing CPT 91034, 91035, 91037, or 91038

---

Aetna Esophageal pH Monitoring Coverage Criteria and Medical Necessity Requirements 2026

CPB 0667 Aetna's updated coverage policy sets specific, condition-by-condition criteria for when esophageal pH monitoring qualifies as medically necessary. The criteria aren't vague. Each covered indication has a defined clinical threshold — and your documentation needs to match it exactly.

Standard catheter-based pH monitoring (CPT 91034) and wireless Bravo capsule monitoring (CPT 91035) are covered for seven distinct indications. Each one has a protocol requirement baked in — either the study is done on PPI therapy, or off it. Get that wrong in your documentation and you're setting up a claim denial before the claim ever leaves your system.

Here's what Aetna requires for each covered indication:

Multi-channel intraluminal impedance (MII) combined with pH testing — CPT 91037 and 91038 — is covered for GERD evaluation in two scenarios: patients with incomplete or no response to PPI therapy who have normal endoscopy, and patients with atypical GERD symptoms like chronic cough. This is the MII-pH combination.

MII combined with esophageal manometry (CPT 91010 with MII) is covered for patients with refractory dysphagia, heartburn, regurgitation, unexplained non-cardiac chest pain, or pre-operative evaluation before anti-reflux surgery.

Multi-channel intraluminal pH impedance testing is covered for GERD evaluation in children and adolescents 18 years of age or younger.

The Bravo capsule (CPT 91035) is an acceptable alternative to catheter-based monitoring for all covered adult indications — except infant vomiting. Don't bill CPT 91035 for that indication. It will not be covered.

Prior authorization requirements aren't explicitly spelled out in the CPB 0667 policy text, but pH monitoring procedures routinely require prior auth under Aetna commercial plans. Verify authorization requirements for your specific plan contract before scheduling. If you're unsure, check with your billing consultant before the study is performed.

---

Aetna Esophageal pH Monitoring Exclusions and Non-Covered Indications

Aetna's coverage policy is direct about what doesn't qualify. These are flat denials — no amount of additional documentation changes the outcome if the indication is on this list.

Esophageal pH recording is not covered for:

The Bravo capsule (CPT 91035) is not covered for:

#	Excluded Procedure Copy
1	Evaluating vomiting in infants. The device isn't approved for this age group. Use catheter-based monitoring (CPT 91034) for that indication or don't bill at all.

Multi-channel intraluminal impedance (MII) testing is considered experimental for:

#	Excluded Procedure Copy
1	Achalasia
2	Laryngo-pharyngeal reflux (LPR)
3	All other indications not specifically listed as covered

The LPR exclusion is worth noting. Chronic cough and laryngitis from suspected GERD can qualify for covered pH monitoring under CPT 91034 or 91035 — but only after a failed four-week PPI trial, and only for symptom documentation. If you're billing MII specifically for LPR, Aetna calls that experimental. That's a distinction with real reimbursement consequences.

Airway pH monitoring is listed as experimental and investigational under this policy. The policy summary was truncated at that point, but the classification is clear. If your providers are performing airway pH studies, don't bill Aetna expecting coverage.

---

Coverage Indications at a Glance

---

Aetna Esophageal pH Monitoring Billing Guidelines and Action Items 2026

This is where the policy update requires real work from your team. The criteria are specific enough that documentation gaps will produce denials. Work through these action items before February 24, 2026.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Esophageal pH Monitoring Under CPB 0667

Covered CPT Codes (When Selection Criteria Are Met)

Key ICD-10-CM Diagnosis Codes

The full code list under CPB 0667 includes 299 ICD-10-CM codes. The table below reflects the codes included in the policy data provided. Descriptions are reproduced exactly as shown in the source data. Full descriptions are available in the complete CPB 0667 policy document on Aetna's website and within PayerPolicy's policy viewer.

219 additional ICD-10-CM codes are available in the complete CPB 0667 policy document on Aetna's website and within PayerPolicy's policy viewer.

---